XAGE-1a and XAGE-1d are potential biomarkers of lung squamous cell carcinoma

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1226-1231

  Ha, Jong Seong ^a,b   Sung, Hye Yeong ^a,d   Kim, Seon Young ^a   Lim, Heon M ^b   Kim, Hark Kyun ^c   Park, Sung Sup ^a,d  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chungnam National University   (South Korea)

^c National Cancer Center   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

Author keywords

Biomarker validation; Lung cancer; Serum biomarkers; XAGE 1a; XAGE 1d

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; PROTEIN CYFRA 21 1; UNCLASSIFIED DRUG; X ANTIGEN FAMILY MEMBER 1; XAGE 1A PROTEIN; XAGE 1D PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; SENSITIVITY AND SPECIFICITY; SUPERNATANT; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BAYES THEOREM; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84861329512     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.03.028     Document Type: Article

References (33)

1. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
2. Mascalchi M., Belli G., Zappa M., et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 2006, 187:421-429.
3. Swensen S.J., Jett J.R., Sloan J.A., et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002, 165:508-513.
4. Maher M.M., Kalra M.K., Toth T.L., Wittram C., Saini S., Shepard J. Application of rational practice and technical advances for optimizing radiation dose for chest CT. J Thorac Imaging 2004, 19:16-23.
5. Mulshine J.L. Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer 2003, 3:65-73.
6. Belinsky S.A. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 2004, 4:707-717.
7. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001, 7:5-22.
8. Bearz A., Berretta M., Cappellani A., et al. Biomarkers in lung cancer. Front Biosci (Elite Ed) 2010, 2:1099-1104.
9. Cho W.C. Latest discoveries and trends in translational cancer research: highlights of the 2008 Annual Meeting of the American Association for Cancer Research. Technol Cancer Res Treat 2008, 7:269-277.
10. Cho W.C. Recent progress in genetic variants associated with cancer and their implications in diagnostics development. Expert Rev Mol Diagn 2010, 10:699-703.
11. Zhao R., Tang B., Liu Y., Zhu N. NLS-dependent and insufficient nuclear localization of XAGE-1 splice variants. Oncol Rep 2011, 25:1083-1089.
12. Kimura Y., Fujii T., Hamamoto K., Miyagawa N., Kataoka M., Iio A. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer 1990, 62:676-678.
13. Alatas F., Alatas O., Metintas M., Colak O., Harmanci E., Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer 2001, 31:9-16.
14. Holdenrieder S., von Pawel J., Dankelmann E., et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008, 14:7813-7821.
15. Cho W.C. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007, 61:515-519.
16. Matsuoka K., Sumitomo S., Nakashima N., Nakajima D., Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007, 32:435-439.
17. Patz E.F., Campa M.J., Gottlin E.B., Kusmartseva I., Guan X.R., Herndon J.E. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007, 25:5578-5583.
18. Mizuguchi S., Nishiyama N., Iwata T., et al. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Lung Cancer 2007, 58:369-375.
19. Qiu Y., Yang H., Chen H., et al. Detection of CEA mRNA, p53 and AE1/AE3 in haematoxylin-eosin-negative lymph nodes of early-stage non-small cell lung cancer may improve veracity of N staging and indicate prognosis. Jpn J Clin Oncol 2010, 40:146-152.
20. Brinkmann U., Vasmatzis G., Lee B., Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999, 59:1445-1448.
21. Zendman A.J., van Kraats A.A., den Hollander A.I., Weidle U.H., Ruiter D.J., van Muijen G.N. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int J Cancer 2002, 97:195-204.
22. Liu X.F., Helman L.J., Yeung C., Bera T.K., Lee B., Pastan I. XAGE-1, a new gene that is frequently expressed in Ewing's sarcoma. Cancer Res 2000, 60:4752-4755.
23. Sato S., Noguchi Y., Ohara N., et al. Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 2007, 7:5.
24. Zendman A.J., Van Kraats A.A., Weidle U.H., Ruiter D.J., Van Muijen G.N. The XAGE family of cancer/testis-associated genes: alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma. Int J Cancer 2002, 99:361-369.
25. Egland K.A., Kumar V., Duray P., Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 2002, 1:441-450.
26. Koizumi F., Noguchi Y., Saika T., et al. XAGE-1 mRNA expression in prostate cancer and antibody response in patients. Microbiol Immunol 2005, 49:471-476.
27. Nakagawa K., Noguchi Y., Uenaka A., et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005, 11:5496-5503.
28. Kikuchi E., Yamazaki K., Nakayama E., et al. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens. Cancer Immun 2008, 8:13.
29. Ali Eldib A.M., Ono T., Shimono M., et al. Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int J Cancer 2004, 108:558-563.
30. Song E.Y., VanDunk C., Kuddo T., Nelson P.G. Measurement of vasoactive intestinal peptide using a competitive fluorescent microsphere immunoassay or ELISA in human blood samples. J Immunol Methods 2005, 300:63-73.
31. Hanley J.A., McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983, 148:839-843.
32. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. The WEKA Data Mining Software: An Update. SIGKDD Explor 2009, 11:10-18.
33. Wang T., Fan L., Watanabe Y., et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001, 20:7699-7709.